--is often part of the protocol for suspected autoimmune molecular mimicry reactions, as are, recently and more experimentally, a number of the immune-suppresant blood cancer drugs.

Autoimmune ganglioneuritis can occur both slowly and acutely, as can many other autoimmune reactions (think MS attack or Gullain Barre syndrome). There is an entity referred to as acute small-fiber sensory neuropathy, in which variants that attack both the nerve endings and the dorsal root ganglia have been described, and the suspicion is a molecular mimicry process:

http://jnnp.bmj.com/content/72/4/540.full

http://neuromuscular.wustl.edu/antib...uron.html#sfsn

In such cases, nerve conduction studies, which only are gross enough to measure problems with larger, meylinated nerves, are unlikely to show any deficit; it might take quantitative sensory testing or skin biopsy to show damage to the smaller fiber nerves.